Kymera Unveils Preclinical Data for KT-621 at ATS Conference
Kymera Therapeutics announced preclinical data for KT-621, an oral STAT6 degrader, showing its potential as a once-daily treatment for...
Championing Change: Expanding Access to Clinical Trials for Working Patients
The Coalition to Transform Clinical Trial Engagement (CTCTE) launched the Champions for Change – Paid Time Off (PTO) Initiative...
Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy for PNH
NovelMed’s Ruxoprubart, a novel complement-targeting immunotherapy, has shown positive interim results in a Phase II trial for Paroxysmal Nocturnal...
Prime Editing Shows Promise in Chronic Disease Treatment
Prime Medicine announced positive initial clinical trial data for PM359, a prime-edited cell therapy for Chronic Granulomatous Disease (CGD)....
Sellas Life Sciences Doses First Pediatric AML Patient in Ongoing Phase 2 Trial
SELLAS Life Sciences Group announced the first pediatric patient with acute myeloid leukemia (AML) has been dosed in a...
EBT-107 Shows Promise in Treating Chronic Hepatitis B
Excision BioTherapeutics announced preclinical data demonstrating the efficacy of EBT-107, a CRISPR-based gene therapy candidate for chronic hepatitis B...
Pacira BioSciences Data: Pre-Existing Treatment Induced Antibodies Do Nnot Impact PCRX-201 for Knee OA
Pacira BioSciences announced preliminary data suggesting that pre-existing and treatment-induced antibodies do not impact the safety and efficacy of...
Voyager’s Novel AAV Capsids Demonstrate BBB Transport in Molecular Therapy
Voyager Therapeutics published data in Molecular Therapy demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV...
BioCryst Pharma: Orladeyo Reduces HAE Attack Rates in Adolescents & Severe Cases
BioCryst Pharmaceuticals announced real-world evidence demonstrating significant and sustained reductions in HAE attack rates for adolescents and individuals with...
Positive Phase 1b Trial Results for TX45 in Pulmonary Hypertension
Tectonic Therapeutic announced complete results from Part A of its Phase 1b clinical trial of TX45 for Group 2...